breast cancer
NICE no for Avastin in breast cancer
December 8, 2010Sales and Marketing NICE, Roche, avastin, bevacizumab, breast cancer, health technology assessment, hta
NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …
FDA approves Eisai breast cancer drug Halaven
November 16, 2010Sales and Marketing Cancer, Eisai, FDA, Halaven, Xeloda, breast cancer, eribulin mesylate, metastatic breast cancer
The FDA has approved Eisai’s advanced breast cancer drug Halaven for use in heavily pre-treated breast cancer patients. Halaven (eribulin …
Roche submits new version of Herceptin for US approval
July 7, 2010Research and Development, Sales and Marketing Herceptin, Roche, breast cancer
Roche has submitted a new version of its blockbuster Herceptin (trastuzumab) to US regulators for approval to treat advanced breast …
European approval for ‘double strength’ Faslodex
March 19, 2010Sales and Marketing AstraZeneca, Faslodex, breast cancer
AstraZeneca’s Faslodex has expanded its European licence after winning approval to treat women with hormone receptor-positive breast cancer in a …
Sanofi’s BSI-201 tipped for success in triple negative breast cancer
February 28, 2010Sales and Marketing Cancer, PARP, Sanofi, breast cancer
Sanofi-Aventis’s BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in 2018, according to …
Sanofi’s breast cancer candidate tipped for future success
February 25, 2010Research and Development, Sales and Marketing BSI-201, Sanofi-Aventis, breast cancer
A Sanofi-Aventis drug currently in phase III has been predicted as a future blockbuster in breast cancer treatment. Sanofi’s BSI-201 …
Nexavar shows promise in breast cancer
September 24, 2009Sales and Marketing Cancer, Nexavar, breast cancer
Bayer’s Nexavar has been shown to significantly extend progression-free survival in patients with advanced breast cancer in a new phase …
Avastin shows promise in advanced breast cancer
August 20, 2009Research and Development, Sales and Marketing Roche, avastin, breast cancer
Avastin's rise continues as new data suggests it improves progression-free survival as a second line treatment for advanced breast cancer.The …
GSK hopeful of NICE approval for Tyverb
January 26, 2009Sales and Marketing Cancer, GSK, breast cancer
NICE could be poised to reverse its rejection of GSK's breast cancer treatment Tyverb, the pharma company has said.NICE rejected …
BMS breast cancer drug rejected
November 27, 2008Sales and Marketing BMS, Cancer, breast cancer
Bristol-Myers Squibb's breast cancer drug Ixempra has suffered a setback in the EU over safety concerns.The Committee for Medicinal Products …
GSK’s pricing deal for Tyverb fails to sway NICE
October 15, 2008Sales and Marketing GSK, NICE, breast cancer
NICE has spurned GSK's risk-sharing proposal for its breast cancer treatment Tyverb, saying the drug is still too expensive to …
Tyverb gains first approval in US
March 14, 2007Sales and Marketing breast cancer
GlaxoSmithKline's breast cancer drug, Tyverb, has been approved in the US and could help women who have failed to respond …
GSK to test Tycerb for head and neck cancer
March 7, 2007Sales and Marketing breast cancer
GlaxoSmithKline is to trial its potential blockbuster Tycerb for a new indication in head and neck cancer.Tycerb was only submitted …
